Next generation gene based therapeutics for cancer treatment and immune modulation

Recent advances in molecular biology, genetic engineering, and biotechnology have accelerated the development of next-generation gene-based therapeutic platforms in oncology. Despite substantial progress in conventional and targeted treatments, limited response durability, therapeutic resistance, and tumor heterogeneity continue to drive the need for more precise, programmable, and personalized therapeutic strategies. In this review, prominent current gene-based therapeutic approaches in the field of cancer treatment and immune modulation have been comprehensively evaluated. In particular, the potential of CRISPR/Cas-based genome editing technologies, RNA-based biotechnological platforms, mRNA and RNA interference (RNAi)-based therapies, and genetically modified immune cell approaches in cancer treatment has been discussed. In addition, the roles of CAR-T and CAR-NK cell engineering, macrophage reprogramming strategies and RNA-mediated immune reprogramming approaches in regulating the tumour microenvironment and enhancing the anti-tumour immune response have been examined. The combination of gene editing technologies, RNA biotechnologies and immune cell engineering is making significant contributions to the development of more targeted, effective and personalised approaches to cancer treatment. Unlike previous reviews that primarily discuss these technologies separately, this review provides a critical comparative evaluation of genome editing, RNA-based therapeutics and engineered immune-cell platforms with respect to their mechanisms, clinical maturity, delivery strategies, safety profiles and translational potential. This integrated perspective highlights complementary therapeutic opportunities and identifies current challenges that must be addressed for the successful implementation of precision oncology.

Authors

Institutions

Publication Details

Journal
Discover Biotechnology
Published
2026-11-13
DOI
https://doi.org/10.1007/s44340-026-00066-x
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Next generation gene based therapeutics for cancer treatment and immune modulation

Harika Topal Önal
4 links
Discover Biotechnology
CAR-T cell therapy research
article

Next generation gene based therapeutics for cancer treatment and immune modulation

Harika Topal Önal
article en

Abstract

Recent advances in molecular biology, genetic engineering, and biotechnology have accelerated the development of next-generation gene-based therapeutic platforms in oncology. Despite substantial progress in conventional and targeted treatments, limited response durability, therapeutic resistance, and tumor heterogeneity continue to drive the need for more precise, programmable, and personalized therapeutic strategies. In this review, prominent current gene-based therapeutic approaches in the field of cancer treatment and immune modulation have been comprehensively evaluated. In particular, the potential of CRISPR/Cas-based genome editing technologies, RNA-based biotechnological platforms, mRNA and RNA interference (RNAi)-based therapies, and genetically modified immune cell approaches in cancer treatment has been discussed. In addition, the roles of CAR-T and CAR-NK cell engineering, macrophage reprogramming strategies and RNA-mediated immune reprogramming approaches in regulating the tumour microenvironment and enhancing the anti-tumour immune response have been examined. The combination of gene editing technologies, RNA biotechnologies and immune cell engineering is making significant contributions to the development of more targeted, effective and personalised approaches to cancer treatment. Unlike previous reviews that primarily discuss these technologies separately, this review provides a critical comparative evaluation of genome editing, RNA-based therapeutics and engineered immune-cell platforms with respect to their mechanisms, clinical maturity, delivery strategies, safety profiles and translational potential. This integrated perspective highlights complementary therapeutic opportunities and identifies current challenges that must be addressed for the successful implementation of precision oncology.

Discover BiotechnologyVol. 3(1)
Toros University (TR)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon